LOXO-195
E564270
LOXO-195 is a next-generation, highly selective TRK inhibitor developed to treat cancers that have developed resistance to earlier TRK-targeted therapies.
Observed surface forms (1)
| Surface form | Occurrences |
|---|---|
| LOXO-101 | 1 |
Statements (42)
| Predicate | Object |
|---|---|
| instanceOf |
TRK inhibitor
ⓘ
investigational drug ⓘ small molecule drug ⓘ targeted cancer therapy ⓘ |
| administeredBy | oral route ⓘ |
| belongsToClass |
protein kinase inhibitors
ⓘ
tyrosine kinase inhibitors ⓘ |
| bindingTarget |
mutant TRK proteins
ⓘ
wild-type TRK proteins ⓘ |
| designedFor | NTRK fusion–positive cancers ⓘ |
| designedToOvercome |
acquired resistance to first-generation TRK inhibitors
ⓘ
gatekeeper mutations in NTRK genes ⓘ solvent-front mutations in NTRK genes ⓘ |
| developedAs | second-generation TRK inhibitor ⓘ |
| developedBy | Loxo Oncology NERFINISHED ⓘ |
| developedInCollaborationWith | Bayer NERFINISHED ⓘ |
| hasAlternativeName |
BAY 2731954
NERFINISHED
ⓘ
selitrectinib NERFINISHED ⓘ |
| hasBiomarker | NTRK gene fusion ⓘ |
| hasDesignGoal |
maintain potency against TRK resistance mutations
ⓘ
minimize off-target kinase inhibition ⓘ |
| hasEffect | inhibition of TRK signaling pathways ⓘ |
| hasIndication |
NTRK fusion–positive solid tumors progressing on larotrectinib
ⓘ
cancers resistant to earlier TRK-targeted therapies ⓘ |
| hasProperty |
highly selective for TRK over other kinases
ⓘ
next-generation TRK inhibitor ⓘ |
| hasResistanceContext | acquired resistance to TRK inhibition ⓘ |
| hasTherapeuticArea | oncology ⓘ |
| investigatedIn | clinical trials ⓘ |
| mechanismOfAction | selective inhibition of TRK kinases ⓘ |
| molecularTargetType | receptor tyrosine kinase ⓘ |
| phaseOfDevelopment | clinical development ⓘ |
| predecessorDrug | larotrectinib NERFINISHED ⓘ |
| targets |
NTRK1
NERFINISHED
ⓘ
NTRK2 NERFINISHED ⓘ NTRK3 NERFINISHED ⓘ tropomyosin receptor kinase A NERFINISHED ⓘ tropomyosin receptor kinase B ⓘ tropomyosin receptor kinase C ⓘ |
| therapeuticModality | small-molecule kinase inhibitor ⓘ |
| usedFor | precision oncology treatment based on NTRK alterations ⓘ |
| usedIn | treatment of solid tumors with NTRK gene fusions ⓘ |
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject surface form:
Loxo Oncology
subject surface form:
Loxo Oncology
this entity surface form:
LOXO-101